TMFM - ETF AI Analysis
Top Page
Motley Fool Mid-Cap Growth ETF (TMFM)
TMFM, the Motley Fool Mid-Cap Growth ETF, has a solid overall rating that reflects a portfolio led by strong growers like Dexcom and Broadridge, whose robust financial performance, positive earnings calls, and strategic initiatives support the fund’s quality. Other key holdings such as HealthEquity, Toast, and MongoDB add to the growth story with strong revenue trends and innovation, though many positions share a common risk of high valuations and, in some cases, bearish or mixed technical signals, which can limit upside and add volatility. The main risk factor is that several of the fund’s major holdings appear potentially overvalued at the same time, making the ETF sensitive to market pullbacks in growth stocks.
TMFM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 109.04M
- Region
- North America
- Expense Ratio
- 0.85%
- Beta
- 0.97
- Issuer
- Motley Fool
- Inception Date
- Dec 10, 2021
- Dividend Yield
- 0.07%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TMFM Summary
The Motley Fool Mid-Cap Growth ETF (TMFM) is an actively managed fund that focuses on medium‑sized U.S. companies with strong growth potential, rather than tracking a traditional index. It leans heavily toward technology and health care businesses, including well-known names like Dexcom and Datadog. Investors might consider TMFM if they want to diversify into mid-sized companies that could grow into the next generation of large, leading firms. However, because it concentrates on growth stocks and specific sectors, its share price can rise and fall more sharply than the overall market.
How much will it cost me?
The Motley Fool Mid-Cap Growth ETF (TMFM) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, relying on expert stock-picking to target mid-cap growth companies with strong potential.
What would affect this ETF?
The TMFM ETF, with its focus on U.S. mid-cap growth companies, could benefit from advancements in technology and innovation, particularly as its largest sector exposure is technology. Positive economic conditions and increased consumer spending may also support growth in sectors like industrials and financials. However, rising interest rates or regulatory changes could negatively impact growth-focused companies, especially in sectors like real estate and financials, which are sensitive to such factors.
TMFM Top 10 Holdings
TMFM is leaning hard into U.S. mid-cap growth, with a clear tilt toward tech and health care names. Datadog has been a bright spot, rising steadily and helping power returns, while Dexcom and Waters are also pulling their weight with solid, if sometimes choppy, momentum. On the other side of the ledger, MongoDB, Axon, and Tyler Technologies have been lagging, acting like sandbags on the fund’s otherwise growthy sail. Overall, it’s a concentrated bet on innovative, software-heavy businesses rather than a broad market mix.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 DXCM | Dexcom | 6.02% | $6.56M | $32.47B | 29.10% | 79Outperform |
 DDOG | Datadog | 5.30% | $5.78M | $88.73B | 70.31% | 69Neutral |
 GWRE | Guidewire | 5.24% | $5.71M | $13.85B | -29.82% | 63Neutral |
 TYL | Tyler Technologies | 4.46% | $4.87M | $14.78B | -28.78% | 66Neutral |
 WAT | Waters | 4.37% | $4.76M | $42.93B | 29.79% | 70Outperform |
 HQY | Healthequity | 4.35% | $4.75M | $7.61B | 1.76% | 76Outperform |
 TOST | Toast Inc | 4.55% | $4.96M | $18.37B | -16.13% | 73Outperform |
 BR | Broadridge Financial Solutions | 4.32% | $4.71M | $19.77B | -23.53% | 78Outperform |
 MDB | MongoDB | 3.90% | $4.25M | $27.19B | 9.47% | 75Outperform |
 AXON | Axon Enterprise | 3.87% | $4.22M | $31.71B | -42.88% | 58Neutral |
TMFM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMFM, the sentiment is Negative. The current price of 21.57 is above the 20-day moving average (MA) of 21.41, below the 50-day MA of 22.17, and below the 200-day MA of 21.81, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 57.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TMFM.
TMFM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TMFM | $21.57 | $23.50(8.97% Upside) | $109.04M | 0.85% | 67Neutral |
 AVMV | $78.32 | $94.30(20.40% Upside) | $792.68M | 0.20% | 71Outperform |
 AVMC | $77.50 | $94.63(22.11% Upside) | $516.66M | 0.18% | 70Outperform |
 GLRY | $36.94 | $48.04(30.05% Upside) | $159.88M | 0.80% | 74Outperform |
 FRTY | $21.60 | $28.20(30.56% Upside) | $144.16M | 0.60% | 60Neutral |
 ACMG | $68.34 | $89.81(31.40% Upside) | $104.83M | 0.39% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TMFM | Motley Fool Mid-Cap Growth ETF | 21.57 | -3.30 | -13.26% | |
| AVMV | Avantis U.S. Mid Cap Value ETF | 78.32 | 10.34 | 15.22% | |
| AVMC | Avantis U.S. Mid Cap Equity ETF | 77.50 | 8.44 | 12.23% | |
| GLRY | Inspire Faithward Mid Cap Momentum ESG ETF | 36.94 | 0.02 | 0.05% | |
| FRTY | Alger Mid Cap 40 ETF | 21.60 | -0.30 | -1.39% | |
| ACMG | American Century Mid Cap Growth Insights ETF | 68.34 | 0.61 | 0.89% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.